Vanguard Global Advisers’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$137K Buy
44,755
+486
+1% +$1.61K ﹤0.01% 2636
2026
Q2
$163K Hold
44,269
– – ﹤0.01% 2577
2026
Q1
$154K Buy
+44,269
New +$168K ﹤0.01% 2552

Other funds holding PRME

Vanguard Global Advisers's PRME Position: Q3 2026 in Review

Vanguard Global Advisers increased its Prime Medicine (PRME) stake by 1.1% in Q3 2026, buying an estimated $1.61K and bringing the position to 44,755 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #2636.

Vanguard Global Advisers first reported a position in PRME in Q1 2026 and has held it in 3 quarters since. The position peaked at $163K in Q2 2026. 185 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

  • Vanguard Global Advisers held 44,755 shares of Prime Medicine worth $137K as of Q3 2026.
  • Vanguard Global Advisers bought 486 Prime Medicine shares in Q3 2026, an estimated $1.61K.
  • Prime Medicine made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2636 holding.
  • Vanguard Global Advisers first reported a position in Prime Medicine in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Prime Medicine position peaked at $163K in Q2 2026.
  • 185 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.